U.S. Ankylosing Spondylitis Market Size & Outlook
U.S. ankylosing spondylitis market, 2016-2027 (US$M)
Related Markets
U.S. ankylosing spondylitis market highlights
- The U.S. ankylosing spondylitis market generated a revenue of USD 2,361.7 million in 2019 and is expected to reach USD 3,997.5 million by 2027.
- The U.S. market is expected to grow at a CAGR of 6.8% from 2020 to 2027.
- In terms of segment, humira was the largest revenue generating drug in 2019.
- Others Drugs is the most lucrative drug segment registering the fastest growth during the forecast period.
Ankylosing spondylitis market data book summary
| Market revenue in 2019 | USD 2,361.7 million |
| Market revenue in 2027 | USD 3,997.5 million |
| Growth rate | 6.8% (CAGR from 2019 to 2027) |
| Largest segment | Humira |
| Fastest growing segment | Others Drugs |
| Historical data | 2016 - 2018 |
| Base year | 2019 |
| Forecast period | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs |
| Key market players worldwide | AbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 56.3% of the global ankylosing spondylitis market in 2019.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. ankylosing spondylitis market is projected to lead the regional market in terms of revenue in 2027.
- Canada is the fastest growing regional market in North America and is projected to reach USD 395.4 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ankylosing Spondylitis Market Scope
Ankylosing Spondylitis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. ankylosing spondylitis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.
Humira was the largest segment with a revenue share of 25.49% in 2019. Horizon Databook has segmented the U.S. ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2016 to 2027.
- U.S. Ankylosing Spondylitis Drug Outlook (Revenue, USD Million, 2016-2027)
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Others Drugs
Reasons to subscribe to U.S. ankylosing spondylitis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. ankylosing spondylitis market databook
-
Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. ankylosing spondylitis market, including forecasts for subscribers. This country databook contains high-level insights into U.S. ankylosing spondylitis market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. ankylosing spondylitis market size, by drug, 2016-2027 (US$M)
U.S. Ankylosing Spondylitis Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
